Financial & Business News
LATEST INVESTING HEADLINES
NEW YORK, NY / ACCESS Newswire / May 5, 2025 / If you suffered a loss on your Open Lending Corporation (NASDAQ:LPRO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/open-lending-corporation-lawsuit-submission-form?prid=146990&wire=1 or contact Joseph E. Levi, Esq.
FDEV is a passively managed ETF that leverages a sophisticated, factor-driven strategy applied to the developed world equities. At this point, FDEV has a Japan-heavy portfolio with a low P/E and financials as the key sector. Its overlap with IDEV is close to 100%. Unfortunately, its long-term returns have been mostly a disappointment, as it has trailed SCHF and IDEV, as well as a few peers.
Axsome Therapeutics, Inc. (NASDAQ:AXSM ) Q1 2025 Earnings Conference Call May 5, 2025 8:00 AM ET Company Participants Darren Opland - Director, Corporate Communications Herriot Tabuteau - CEO Nick Pizzie - CFO Ari Maizel - Chief Commercial Officer Mark Jacobson - COO Hunter Murdock - General Counsel Conference Call Participants Leonid Timashev - RBC Capital Markets Marc Goodman - Leerink Partners Andrew Tsai - Jefferies Ash Verma - UBS Ram Selvaraju - H.C. Wainwright Charles Duncan - Cantor Fitzgerald David Amsellem - Piper Sandler David Hoang - Deutsche Bank Joon Lee - Truist Securities Cerena Chen - Wells Fargo Jason Gerberry - Bank of America Graig Suvannavejh - Mizuho Securities Yatin Suneja - Guggenheim Partners Myles Minter - William Blair Troy Langford - TD Cowen Ami Fadia - Needham & Company Operator Greetings, and welcome to the Axsome Therapeutics First Quarter 2025 Conference Call and Webcast.
NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Viatris, Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
The U.S. Food and Drug Administration (FDA) has approved Teva Pharmaceutical Industries Ltd. TEVA and Alvotech's ALVO Selarsdi (ustekinumab-aekn) injection as interchangeable with the reference biologic Johnson & Johnson's JNJ Stelara (ustekinumab).
Twist Bioscience Corporation (NASDAQ:TWST ) Q2 2025 Earnings Conference Call April 5, 2025 8:00 AM ET Company Participants Angela Bitting - Senior Vice President of Corporate Affairs Emily Leproust - Chief Executive Officer Patrick Finn - President and Chief Operating Officer Adam Laponis - Chief Financial Officer Conference Call Participants Luke Sergott - Barclays Matthew Sykes - Goldman Sachs Subbu Nambi - Guggenheim Securities Doug Schenkel - Wolfe Research Vijay Kumar - Evercore ISI Matt Larew - William Blair Puneet Souda - Leerink Partners Sung-Ji Nam - Scotiabank Thomas Peterson - Baird Brendan Smith - TD Cowen Operator Good day. Thank you for standing by.
NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Open Lending Corporation. (“Open Lending” or the “Company”) (NASDAQ: LPRO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
BG's Q1 results are anticipated to reflect weak year-over-year performances in its segments and the impacts of the divestiture of the Sugar and Bioenergy segment.
BioNTech SE (NASDAQ:BNTX ) Q1 2025 Earnings Conference Call May 5, 2025 8:00 AM ET Company Participants Michael Horowicz - Director, Investor Relations Ugur Sahin - Co-Founder & Chief Executive Officer Özlem Türeci - Co-Founder & Chief Medical Officer Jens Holstein - Chief Financial Officer Ryan Richardson - Chief Strategy Officer Conference Call Participants Tazeen Ahmad - Bank of America Akash Tewari - Jefferies Daina Graybosch - Leerink Partners Cory Kasimov - Evercore Terence Flynn - Morgan Stanley Jessica Fye - JPMorgan Evan Seigerman - BMO Capital Markets Yaron Werber - TD Cowen Mohit Bansal - Wells Fargo Harry Gillis - Berenberg John Newman - Canaccord Genuity Operator Welcome to BioNTech's First Quarter 2025 Earnings Call. I would like to hand the call over to Michael Horowicz, Director, Investor Relations.
NEW YORK, May 05, 2025 – PRISM MediaWire – AB International Group Corp.